Skip to main content
Grafa
Health
Biomerica announces $4.5 million fiscal revenue
Image for illustrative purposes only. Not a real photo.

Biomerica announces $4.5 million fiscal revenue

Share
  • Biomerica reported fiscal 2026 revenue of approximately $4.50 million and a reduced net loss.
  • Fourth-quarter sales increased 17% year over year to $875,000.
  • The company advanced commercialization efforts for inFoods IBS and hp+detect products.

Biomerica (NASDAQ:BMRA) reported fiscal 2026 revenue of approximately $4.50 million, down from $5.30 million in fiscal 2025, while net loss improved to $3.8 million.

The company’s fiscal results included gross margin of about 8%, compared with prior-year results, and benefited from $1.1 million in Employee Retention Credit income and a $335,000 unrealized gain on its Diagnosis S.A. investment.

Biomerica reported fourth-quarter net sales of approximately $875,000, up about 17% year over year, while research and development expenses declined 23% to $788,000 as inFoods IBS and hp+detect moved toward commercialization.

The company said inFoods IBS achieved Medicare reimbursement progress with initial valid claims paid at the full $300 CMS rate.

Biomerica develops diagnostic tests and healthcare products, including its inFoods IBS diagnostic-guided therapy platform and hp+detect H. pylori test.

The company also reported a $1.75 million CDMO development agreement, first commercial orders for hp+detect in Europe, an AI-supported dietary tool launch, and a post-year-end $2.23 million equity raise.

Frequently asked questions